243 related articles for article (PubMed ID: 25140871)
41. Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses.
Holtsberg FW; Shulenin S; Vu H; Howell KA; Patel SJ; Gunn B; Karim M; Lai JR; Frei JC; Nyakatura EK; Zeitlin L; Douglas R; Fusco ML; Froude JW; Saphire EO; Herbert AS; Wirchnianski AS; Lear-Rooney CM; Alter G; Dye JM; Glass PJ; Warfield KL; Aman MJ
J Virol; 2016 Jan; 90(1):266-78. PubMed ID: 26468533
[TBL] [Abstract][Full Text] [Related]
42. Asymmetric and non-stoichiometric glycoprotein recognition by two distinct antibodies results in broad protection against ebolaviruses.
Milligan JC; Davis CW; Yu X; Ilinykh PA; Huang K; Halfmann PJ; Cross RW; Borisevich V; Agans KN; Geisbert JB; Chennareddy C; Goff AJ; Piper AE; Hui S; Shaffer KCL; Buck T; Heinrich ML; Branco LM; Crozier I; Holbrook MR; Kuhn JH; Kawaoka Y; Glass PJ; Bukreyev A; Geisbert TW; Worwa G; Ahmed R; Saphire EO
Cell; 2022 Mar; 185(6):995-1007.e18. PubMed ID: 35303429
[TBL] [Abstract][Full Text] [Related]
43. Structural Basis of Pan-Ebolavirus Neutralization by a Human Antibody against a Conserved, yet Cryptic Epitope.
West BR; Moyer CL; King LB; Fusco ML; Milligan JC; Hui S; Saphire EO
mBio; 2018 Sep; 9(5):. PubMed ID: 30206174
[TBL] [Abstract][Full Text] [Related]
44. Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies.
Qiu X; Alimonti JB; Melito PL; Fernando L; Ströher U; Jones SM
Clin Immunol; 2011 Nov; 141(2):218-27. PubMed ID: 21925951
[TBL] [Abstract][Full Text] [Related]
45. Single-Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge.
Matassov D; Mire CE; Latham T; Geisbert JB; Xu R; Ota-Setlik A; Agans KN; Kobs DJ; Wendling MQS; Burnaugh A; Rudge TL; Sabourin CL; Egan MA; Clarke DK; Geisbert TW; Eldridge JH
J Virol; 2018 Feb; 92(3):. PubMed ID: 29142131
[TBL] [Abstract][Full Text] [Related]
46. Achieving cross-reactivity with pan-ebolavirus antibodies.
King LB; Milligan JC; West BR; Schendel SL; Ollmann Saphire E
Curr Opin Virol; 2019 Feb; 34():140-148. PubMed ID: 30884329
[TBL] [Abstract][Full Text] [Related]
47. STAT-1 Knockout Mice as a Model for Wild-Type Sudan Virus (SUDV).
Escaffre O; Juelich TL; Neef N; Massey S; Smith J; Brasel T; Smith JK; Kalveram B; Zhang L; Perez D; Ikegami T; Freiberg AN; Comer JE
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372594
[TBL] [Abstract][Full Text] [Related]
48. Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER region.
Flyak AI; Kuzmina N; Murin CD; Bryan C; Davidson E; Gilchuk P; Gulka CP; Ilinykh PA; Shen X; Huang K; Ramanathan P; Turner H; Fusco ML; Lampley R; Kose N; King H; Sapparapu G; Doranz BJ; Ksiazek TG; Wright DW; Saphire EO; Ward AB; Bukreyev A; Crowe JE
Nat Microbiol; 2018 Jun; 3(6):670-677. PubMed ID: 29736037
[TBL] [Abstract][Full Text] [Related]
49. Epitope-focused immunogen design based on the ebolavirus glycoprotein HR2-MPER region.
Schoeder CT; Gilchuk P; Sangha AK; Ledwitch KV; Malherbe DC; Zhang X; Binshtein E; Williamson LE; Martina CE; Dong J; Armstrong E; Sutton R; Nargi R; Rodriguez J; Kuzmina N; Fiala B; King NP; Bukreyev A; Crowe JE; Meiler J
PLoS Pathog; 2022 May; 18(5):e1010518. PubMed ID: 35584193
[TBL] [Abstract][Full Text] [Related]
50. Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses.
Wec AZ; Herbert AS; Murin CD; Nyakatura EK; Abelson DM; Fels JM; He S; James RM; de La Vega MA; Zhu W; Bakken RR; Goodwin E; Turner HL; Jangra RK; Zeitlin L; Qiu X; Lai JR; Walker LM; Ward AB; Dye JM; Chandran K; Bornholdt ZA
Cell; 2017 May; 169(5):878-890.e15. PubMed ID: 28525755
[TBL] [Abstract][Full Text] [Related]
51. Design and characterization of protective pan-ebolavirus and pan-filovirus bispecific antibodies.
Wirchnianski AS; Nyakatura EK; Herbert AS; Kuehne AI; Abbasi SA; Florez C; Storm N; McKay LGA; Dailey L; Kuang E; Abelson DM; Wec AZ; Chakraborti S; Holtsberg FW; Shulenin S; Bornholdt ZA; Aman MJ; Honko AN; Griffiths A; Dye JM; Chandran K; Lai JR
PLoS Pathog; 2024 Apr; 20(4):e1012134. PubMed ID: 38603762
[TBL] [Abstract][Full Text] [Related]
52. Profiling the native specific human humoral immune response to Sudan Ebola virus strain Gulu by chemiluminescence enzyme-linked immunosorbent assay.
Sobarzo A; Perelman E; Groseth A; Dolnik O; Becker S; Lutwama JJ; Dye JM; Yavelsky V; Lobel L; Marks RS
Clin Vaccine Immunol; 2012 Nov; 19(11):1844-52. PubMed ID: 22993411
[TBL] [Abstract][Full Text] [Related]
53. Structural and molecular basis for Ebola virus neutralization by protective human antibodies.
Misasi J; Gilman MS; Kanekiyo M; Gui M; Cagigi A; Mulangu S; Corti D; Ledgerwood JE; Lanzavecchia A; Cunningham J; Muyembe-Tamfun JJ; Baxa U; Graham BS; Xiang Y; Sullivan NJ; McLellan JS
Science; 2016 Mar; 351(6279):1343-6. PubMed ID: 26917592
[TBL] [Abstract][Full Text] [Related]
54. Homologous and heterologous protection of nonhuman primates by Ebola and Sudan virus-like particles.
Warfield KL; Dye JM; Wells JB; Unfer RC; Holtsberg FW; Shulenin S; Vu H; Swenson DL; Bavari S; Aman MJ
PLoS One; 2015; 10(3):e0118881. PubMed ID: 25793502
[TBL] [Abstract][Full Text] [Related]
55. Cross-protection conferred by filovirus virus-like particles containing trimeric hybrid glycoprotein.
Martins K; Carra JH; Cooper CL; Kwilas SA; Robinson CG; Shurtleff AC; Schokman RD; Kuehl KA; Wells JB; Steffens JT; van Tongeren SA; Hooper JW; Bavari S
Viral Immunol; 2015 Feb; 28(1):62-70. PubMed ID: 25514232
[TBL] [Abstract][Full Text] [Related]
56. Neutralizing the Threat: Pan-Ebolavirus Antibodies Close the Loop.
Mire CE; Geisbert TW
Trends Mol Med; 2017 Aug; 23(8):669-671. PubMed ID: 28697885
[TBL] [Abstract][Full Text] [Related]
57. Analysis of a Therapeutic Antibody Cocktail Reveals Determinants for Cooperative and Broad Ebolavirus Neutralization.
Gilchuk P; Murin CD; Milligan JC; Cross RW; Mire CE; Ilinykh PA; Huang K; Kuzmina N; Altman PX; Hui S; Gunn BM; Bryan AL; Davidson E; Doranz BJ; Turner HL; Alkutkar T; Flinko R; Orlandi C; Carnahan R; Nargi R; Bombardi RG; Vodzak ME; Li S; Okoli A; Ibeawuchi M; Ohiaeri B; Lewis GK; Alter G; Bukreyev A; Saphire EO; Geisbert TW; Ward AB; Crowe JE
Immunity; 2020 Feb; 52(2):388-403.e12. PubMed ID: 32023489
[TBL] [Abstract][Full Text] [Related]
58. Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak.
Bornholdt ZA; Turner HL; Murin CD; Li W; Sok D; Souders CA; Piper AE; Goff A; Shamblin JD; Wollen SE; Sprague TR; Fusco ML; Pommert KB; Cavacini LA; Smith HL; Klempner M; Reimann KA; Krauland E; Gerngross TU; Wittrup KD; Saphire EO; Burton DR; Glass PJ; Ward AB; Walker LM
Science; 2016 Mar; 351(6277):1078-83. PubMed ID: 26912366
[TBL] [Abstract][Full Text] [Related]
59. Differential requirements for FcγR engagement by protective antibodies against Ebola virus.
Bournazos S; DiLillo DJ; Goff AJ; Glass PJ; Ravetch JV
Proc Natl Acad Sci U S A; 2019 Oct; 116(40):20054-20062. PubMed ID: 31484758
[TBL] [Abstract][Full Text] [Related]
60. Development and Characterization of Broadly Cross-reactive Monoclonal Antibodies Against All Known Ebolavirus Species.
Hernandez H; Marceau C; Halliday H; Callison J; Borisevich V; Escaffre O; Creech J; Feldmann H; Rockx B
J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S410-3. PubMed ID: 25999057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
